Connect
MJA
MJA

Metformin use as an adjunct to insulin treatment in selected patients with type 1 diabetes mellitus

Jenny E Gunton and Stephen M Twigg
Med J Aust 2003; 178 (11) || doi: 10.5694/j.1326-5377.2003.tb05374.x
Published online: 2 June 2003

To the Editor: Metformin is a commonly prescribed oral hypoglycaemic agent used to treat type 2 diabetes mellitus. Its major effect is on hepatic glucose production and thereby fasting blood glucose level (f-BGL). Metformin does not commonly cause weight gain, and may be associated with significant weight loss.1

The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.




Correspondence: 

Acknowledgements: 

Jenny E Gunton is supported by the National Health and Medical Research Council CJ Martin Fellowship.

Competing interests:

None identified.

  • 1. Bailey CJ, Turner RC. Drug therapy: metformin. N Engl J Med 1996; 334: 574-579.
  • 2. Daniel JR, Hagmeyer KO. Metformin and insulin: is there a role for combination therapy? Ann Pharmacother 1997; 31: 474-480.
  • 3. Meyer L, Bohme P, Delbachian I, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002; 25: 2153-2158.
  • 4. Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomised controlled trial. Diabetes Care 2003; 26: 138-143.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.